The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients

Transplantation Reviews

Volumn 28, Issue 2, 2014, Pages 84-91

  Roman, Antonio ^a   Manito, Nicolás ^b   Campistol, Josep Maria ^c   Cuervas Mons, Valentín ^d   Almenar, Luis ^e   Arias, Manuel ^f   Casafont, Fernando ^f   del Castillo, Domingo ^g   Crespo Leiro, María G ^h   Delgado, Juan F ⁱ   Herrero, J Ignacio ^j   Jara, Paloma ^k   Morales, José M ⁱ   Navarro, Mercedes ^k   Oppenheimer, Federico ^c   Prieto, Martín ^e   Pulpón, Luis A ^d   Rimola, Antoni ^c   Serón, Daniel ^a   Ussetti, Piedad ^d  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h UNIVERSITY OF A CORUÑA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j UNIVERSITY CLINIC OF NAVARRA   (Spain)

^k HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CELL ADHESION MOLECULE; CYTOKINE; FC RECEPTOR; GANCICLOVIR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VALACICLOVIR; VALGANCICLOVIR; VON WILLEBRAND FACTOR;

ACUTE GRAFT REJECTION; ANTIGEN PRESENTING CELL; ANTIVIRAL THERAPY; B LYMPHOCYTE ACTIVATION; CARDIAC ALLOGRAFT VASCULOPATHY; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC GRAFT REJECTION; CYTOKINE RELEASE; CYTOMEGALOVIRUS INFECTION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; EPITHELIUM CELL; GRAFT DYSFUNCTION; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNE EVASION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; META ANALYSIS (TOPIC); OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PLASMACYTOID DENDRITIC CELL; PROPHYLAXIS; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID ORGAN TRANSPLANTATION; SURGICAL MORTALITY; SURVIVAL RATE; SYSTEMIC CIRCULATION; VIRUS IMMUNITY; VIRUS REPLICATION; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT REJECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INCIDENCE; MALE; PRIMARY PREVENTION; PROCEDURES; PROGNOSIS; SURVIVAL;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; PRIMARY PREVENTION; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84897082126     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2014.01.001     Document Type: Review

References (104)

1. American Society of Transplantation Cytomegalovirus. Am J Transplant 2004, 4:51-58.
2. de la Torre-Cisneros J., Farinas M.C., Caston J.J., et al. GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients. Enferm Infecc Microbiol Clin 2011, 29:735-758.
3. McDevitt L.M. Etiology and impact of cytomegalovirus disease on solid organ transplant recipients. Am J Health Syst Pharm 2006, 63:S3-S9.
4. Manuel O., Husain S., Kumar D., et al. Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013, 56:817-824.
5. Meyer-Koenig U., Weidmann M., Kirste G., Hufert F.T. Cytomegalovirus infection in organ-transplant recipients: diagnostic value of pp 65 antigen test, qualitative polymerase chain reaction (PCR) and quantitative Taqman PCR. Transplantation 2004, 77:1692-1698.
6. Baldanti F., Lilleri D., Gerna G. Monitoring human cytomegalovirus infection in transplant recipients. J Clin Virol 2008, 41:237-241.
7. Fishman J.A., Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 1998, 338:1741-1751.
8. Paya C.V. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis 1999, 1:8-12.
9. Cantisán S., Torre-Cisneros J., Lara R., et al. Age-dependent association between low frequency of CD27/CD28 expression on pp 65 CD8+ T cells and cytomegalovirus replication after transplantation. Clin Vaccine Immunol 2009, 16:1429-1438.
10. Sagedal S., Nordal K.P., Hartmann A., et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002, 2:850-856.
11. Becker B.N., Becker Y.T., Leverson G.E., Simmons W.D., Sollinger H.W., Pirsch J.D. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis 2002, 39:1088-1095.
12. Toupance O., Bouedjoro-Camus M.C., Carquin J., et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses. Transpl Int 2000, 13:413-419.
13. Pouteil-Noble C., Ecochard R., Landrivon G., et al. Cytomegalovirus infection - an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 1993, 55:851-857.
14. Ricart M.J., Malaise J., Moreno A., Crespo M., Fernandez-Cruz L. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 2005, 20:ii25-ii32. [ii62].
15. Kranz B., Vester U., Wingen A.M., et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant 2008, 12:474-478.
16. Boratynska M., Banasik M., Watorek E., Patrzalek D., Szyber P., Klinger M. Influence of cytomegalovirus disease on early and late renal graft function. Transplant Proc 2006, 38:147-150.
17. Reischig T., Jindra P., Hes O., Bouda M., Kormunda S., Treska V. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 2009, 87:436-444.
18. Humar A., Gillingham K.J., Payne W.D., Dunn D.L., Sutherland D.E., Matas A.J. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999, 68:1879-1883.
19. Solà R., Díaz J.M., Guirado L., et al. Significance of cytomegalovirus infection in renal transplantation. Transplant Proc 2003, 35:1753-1755.
20. Dzabic M., Rahbar A., Yaiw K.C., et al. Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival. Clin Infect Dis 2011, 53:969-976.
21. Tong C.Y., Bakran A., Peiris J.S., Muir P., Herrington C.S. The association of viral infection and chronic allograft nephropathy with graft dysfunction after renal transplantation. Transplantation 2002, 74:576-578.
22. van Ree R.M., de Vries A.P., Zelle D.M., et al. Latent cytomegalovirus infection is an independent risk factor for late graft failure in renal transplant recipients. Med Sci Monit 2011, 17:CR609-CR617.
23. Dickenmann M.J., Cathomas G., Steiger J., Mihatsch M.J., Thiel G., Tamm M. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation 2001, 71:764-767.
24. Giral M., Nguyen J.M., Daguin P., et al. Mycophenolate mofetil does not modify the incidence of cytomegalovirus (CMV) disease after kidney transplantation but prevents CMV-induced chronic graft dysfunction. J Am Soc Nephrol 2001, 12:1758-1763.
25. Schnitzler M.A., Lowell J.A., Hmiel S.P., et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of HLA-DR matching. J Am Soc Nephrol 2003, 14:780-785.
26. Helanterä I., Koskinen P., Finne P., et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int 2006, 19:893-900.
27. Browne B.J., Young J.A., Dunn T.B., Matas A.J. The impact of cytomegalovirus infection >/=1year after primary renal transplantation. Clin Transplant 2010, 24:572-577.
28. Sagedal S., Hartmann A., Nordal K.P., et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004, 66:329-337.
29. Sagedal S., Rollag H., Hartmann A. Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin Transplant 2007, 21:309-313.
30. Nett P.C., Heisey D.M., Fernandez L.A., Sollinger H.W., Pirsch J.D. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 2004, 78:1036-1041.
31. Ozdemir F.N., Akgul A., Altunoglu A., Bilgic A., Arat Z., Haberal M. The association between cytomegalovirus infection and atherosclerotic events in renal transplant recipients. Transplant Proc 2007, 39:990-992.
32. Gómez E., Laurés A., Baltar J.M., Melón S., Diez B., de Oña M. Cytomegalovirus replication and "herpesvirus burden" as risk factor of cardiovascular events in the first year after renal transplantation. Transplant Proc 2005, 37:3760-3763.
33. Humar A., Gillingham K., Payne W.D., Sutherland D.E., Matas A.J. Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease. Transplantation 2000, 70:310-313.
34. Hjelmesaeth J., Sagedal S., Hartmann A., et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004, 47:1550-1556.
35. Hjelmesaeth J., Jenssen T., Hagen M., Egeland T., Hartmann A. Determinants of insulin secretion after renal transplantation. Metabolism 2003, 52:573-578.
36. Abou-Ayache R., Buchler M., Le P.P., et al. The influence of cytomegalovirus infections on patient and renal graft outcome: a 3-year, multicenter, observational study (Post-ECTAZ Study). Transplant Proc 2011, 43:2630-2635.
37. Evans P.C., Soin A., Wreghitt T.G., Taylor C.J., Wight D.G., Alexander G.J. An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 2000, 69:30-35.
38. Burak K.W., Kremers W.K., Batts K.P., et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002, 8:362-369.
39. Razonable R.R., Burak K.W., van Cruijsen H., et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002, 35:974-981.
40. de Otero J., Gavalda J., Murio E., et al. Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. Clin Infect Dis 1998, 26:865-870.
41. Falagas M.E., Paya C., Ruthazer R., et al. Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. Transplantation 1998, 66:1020-1028.
42. Bosch W., Heckman M.G., Diehl N.N., Shalev J.A., Pungpapong S., Hellinger W.C. Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients. Am J Transplant 2011, 11:2181-2189.
43. Kim J.M., Kim S.J., Joh J.W., et al. Is cytomegalovirus infection dangerous in cytomegalovirus-seropositive recipients after liver transplantation?. Liver Transpl 2011, 17:446-455.
44. Shibolet O., Ilan Y., Kalish Y., et al. Late cytomegalovirus disease following liver transplantation. Transpl Int 2003, 16:861-865.
45. Paya C.V., Wiesner R.H., Hermans P.E., et al. Lack of association between cytomegalovirus infection, HLA matching and the vanishing bile duct syndrome after liver transplantation. Hepatology 1992, 16:66-70.
46. Chopra K.B., Demetris A.J., Blakolmer K., et al. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 2003, 76:1487-1491.
47. Driscoll C.J., Cashion A.K., Hathaway D.K., et al. Posttransplant diabetes mellitus in liver transplant recipients. Prog Transplant 2006, 16:110-116.
48. Manez R., Breinig M.C., Linden P., et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis 1997, 176:1462-1467.
49. Fateh-Moghadam S., Bocksch W., Wessely R., Jager G., Hetzer R., Gawaz M. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation 2003, 76:1470-1474.
50. Grattan M.T., Moreno-Cabral C.E., Starnes V.A., Oyer P.E., Stinson E.B., Shumway N.E. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989, 261:3561-3566.
51. Potena L., Grigioni F., Ortolani P., et al. Relevance of cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. Transplantation 2003, 75:839-843.
52. Hussain T., Burch M., Fenton M.J., et al. Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children. Circulation 2007, 115:1798-1805.
53. Koskinen P.K., Krogerus L.A., Nieminen M.S., Mattila S.P., Hayry P.J., Lautenschlager I.T. Quantitation of cytomegalovirus infection-associated histologic findings in endomyocardial biopsies of heart allografts. J Heart Lung Transplant 1993, 12:343-354.
54. Petrakopoulou P., Kubrich M., Pehlivanli S., et al. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation 2004, 110:II207-II212.
55. Kalil R.S., Hudson S.L., Gaston R.S. Determinants of cardiovascular mortality after renal transplantation: a role for cytomegalovirus?. Am J Transplant 2003, 3:79-81.
56. Simmonds J., Fenton M., Dewar C., et al. Endothelial dysfunction and cytomegalovirus replication in pediatric heart transplantation. Circulation 2008, 117:2657-2661.
57. Weis M., Kledal T.N., Lin K.Y., et al. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation 2004, 109:500-505.
58. Navarro-Manchón J., Martínez-Dolz L., Almenar Bonet L., et al. Predictors of renal dysfunction at 1 year in heart transplant patients. Transplantation 2010, 89:977-982.
59. Avery R.K. Special considerations regarding CMV in lung transplantation. Transpl Infect Dis 1999, 1:13-18.
60. Schlesinger C., Meyer C.A., Veeraraghavan S., Koss M.N. Constrictive (obliterative) bronchiolitis: diagnosis, etiology, and a critical review of the literature. Ann Diagn Pathol 1998, 2:321-334.
61. Westall G.P., Michaelides A., Williams T.J., Snell G.I., Kotsimbos T.C. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation 2003, 75:2064-2068.
62. Keenan R.J., Lega M.E., Dummer J.S., et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 1991, 51:433-438.
63. Duncan S.R., Paradis I.L., Yousem S.A., et al. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis 1992, 146:1419-1425.
64. Kroshus T.J., Kshettry V.R., Savik K., John R., Hertz M.I., Bolman R.M. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997, 114:195-202.
65. Paraskeva M., Bailey M., Levvey B.J., et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 2011, 11:2190-2196.
66. Johanssson I., Martensson G., Andersson R. Cytomegalovirus and long-term outcome after lung transplantation in Gothenburg, Sweden. Scand J Infect Dis 2010, 42:129-136.
67. Danziger-Isakov L.A., DelaMorena M., Hayashi R.J., et al. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation 2003, 75:1538-1543.
68. Kerschner H., Jaksch P., Karigl G., Popow-Kraupp T., Klepetko W., Puchhammer-Stockl E. Cytomegalovirus DNA load patterns developing after lung transplantation are significantly correlated with long-term patient survival. Transplantation 2009, 87:1720-1726.
69. Varani S., Landini M.P. Cytomegalovirus-induced immunopathology and its clinical consequences. Herpesviridae 2011, 2:6.
70. Crough T., Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev 2009, 22:76-98. [Table].
71. Fishman J.A., Emery V., Freeman R., et al. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 2007, 21:149-158.
72. Freeman R.B. The 'indirect' effects of cytomegalovirus infection. Am J Transplant 2009, 9:2453-2458.
73. Streblow D.N., Orloff S.L., Nelson J.A. Acceleration of allograft failure by cytomegalovirus. Curr Opin Immunol 2007, 19:577-582.
74. Söderberg-Nauclér C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?. J Intern Med 2006, 259:219-246.
75. Varani S., Frascaroli G., Landini M.P., Soderberg-Naucler C. Human cytomegalovirus targets different subsets of antigen-presenting cells with pathological consequences for host immunity: implications for immunosuppression, chronic inflammation and autoimmunity. Rev Med Virol 2009, 19:131-145.
76. Couzi L., Levaillant Y., Jamai A., et al. Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation. J Am Soc Nephrol 2010, 21:181-188.
77. Spinner M.L., Saab G., Casabar E., Bowman L.J., Storch G.A., Brennan D.C. Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes. Transplantation 2010, 90:412-418.
78. Kalil A.C., Levitsky J., Lyden E., Stoner J., Freifeld A.G. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005, 143:870-880.
79. Hodson E.M., Jones C.A., Webster A.C., et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005, 365:2105-2115.
80. Hodson E.M., Craig J.C., Strippoli G.F.M., Webster A.C. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2008, CD003774. 10.1002/14651858.CD003774.pub3.
81. Opelz G., Dohler B., Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004, 4:928-936.
82. Kliem V., Fricke L., Wollbrink T., Burg M., Radermacher J., Rohde F. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008, 8:975-983.
83. Humar A., Lebranchu Y., Vincenti F., et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010, 10:1228-1237.
84. Gracia-Ahufinger I., Gutierrez-Aroca J., Cordero E., et al. Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations. Transplantation 2013, 95:1015-1020.
85. Winston D.J., Busuttil R.W. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Transplantation 2003, 75:229-233.
86. Shiley K.T., Gasink L.B., Barton T.D., Pfeiffenberger P., Olthoff K.M., Blumberg E.A. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis. Liver Transpl 2009, 15:963-967.
87. Singh N., Wannstedt C., Keyes L., Wagener M.M., Gayowski T., Cacciarelli T.V. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13 years. Transplantation 2005, 79:1428-1434.
88. Delgado J.F., Manito N., Almenar L., et al. Risk factors associated with cytomegalovirus infection in heart transplant patients: a prospective, epidemiological study. Transpl Infect Dis 2011, 13:136-144.
89. Valantine H.A., Gao S.Z., Menon S.G., et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999, 100:61-66.
90. Potena L., Holweg C.T., Chin C., et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006, 82:398-405.
91. Potena L., Grigioni F., Magnani G., et al. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 2009, 28:461-467.
92. Sharples L.D., McNeil K., Stewart S., Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002, 21:271-281.
93. Soghikian M.V., Valentine V.G., Berry G.J., Patel H.R., Robbins R.C., Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant 1996, 15:881-887.
94. Speich R., Thurnheer R., Gaspert A., Weder W., Boehler A. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation 1999, 67:315-320.
95. Manuel O., Kumar D., Moussa G., et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009, 87:719-725.
96. Ruttmann E., Geltner C., Bucher B., et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 2006, 81:1415-1420.
97. Solidoro P., Libertucci D., Delsedime L., et al. Combined cytomegalovirus prophylaxis in lung transplantation: effects on acute rejection, lymphocytic bronchitis/bronchiolitis, and herpesvirus infections. Transplant Proc 2008, 40:2013-2014.
98. Chmiel C., Speich R., Hofer M., et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008, 46:831-839.
99. Valentine V.G., Weill D., Gupta M.R., et al. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant 2008, 27:875-881.
100. Razonable R.R. Immune-based therapies for cytomegalovirus infection. Immunotherapy 2010, 2:117-130.
101. Hodson E.M., Jones C.A., Strippoli G.F.M., Webster A.C., Craig J.C. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2007, CD005129. 10.1002/14651858.CD005129.pub2.
102. Griffiths P.D., Stanton A., McCarrell E., et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256-1263.
103. Boeckh M. Complications, diagnosis, management, and prevention of CMV infections: current and future. Hematology Am Soc Hematol Educ Program 2011, 2011:305-309.
104. Kotton C.N. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol 2010, 6:711-721.